Neurokinin I receptor antagonist (NK1RA) fosaprepitant is a new antiemetic drug. Fosaprepitant dimeglumine was ap-proved by FDA in January 2008, while it is still in the approval stage in China. Fosaprepitant, as a prodrug of aprepitant, is rapidly converted to aprepitant after intravenous administration in vivo. The indication of fosaprepitant is the prevention of chemotherapy in-duced nausea and vomiting ( CINV) , especially the delayed CINV. Fosaprepitant as a unique intravenous preparation overcomes the drawbacks of aprepitant with oral administration only. Its bioavailability is not affected by the vomiting of patients. It is also suitable for patients with oral mucositis, who are unfavorable for oral medication. The action mechanisms, pharmacokinetics, and clinical trials of fosaprepitant were reviewed in the paper.

Several aquatic species and their enviroments were examined for presence of Vibrio parahaemo-lyticus between 2007 and 2008 in the coastal areas in Zhejiang province, and some virulence-related genes such as tdh, trh, ureC and vscC2 were investigated from the isolates. V. parahaemolyticus was recovered from 70% of the samples tested (395/566). The genes tdh, trh and ureC existed in 10.1%, 20.0% and 11.1% respectively from 395 isolates. Among the 40 tdh-positive isolates, 32.5% harbored the vscC2 gene, one of the type three secretion system 2 (T3SS2) gene family. Thirty-eight of the 40 tdh-positive isolates were positive for the Kanagawa phenomenon. Out of 44 trh-and-ureC-positive isolates, only six exhibited urease phenotype. Overall, this study reveals the significant prevalence of Vibrio parahaemolyticus in seafoods and their habitats with high diversity of virulence genes. Representative V. parahaemolyticus isolates could beused for further investigation into their pathongenecity, functional genomics, and molecular evolution.

Objective To evaluate the value of DWI and ADC value in monitoring the chemotherapy response of advanced gastric carcinoma dynamically.Methods 42 advanced gastric carcinoma patients who were confirmed by histopathology underwent T2 WI and DWI examinations at pre-chemotherapy,post-chemotherapy 3 d,7 d,30 d and 60 d respectively.The longest diameters of tumor pre-chemotherapy and post-chemotherapy 60 d were measured on axial T2 WI,meanwhile the ADC values at different time points were calculated.The mean ADC value among pre-and post-chemotherapy of each group (PR and SD)was compared.Results The ADC value of PR group increased gradually.The mean ADC value before therapy was statistically lower than those at differ-ent time points post-chemotherapy (P < 0.05).The ADC value of SD group increased gradually from pre-chemotherapy to post-chemotherapy 30 d,and then the ADC value decreased at post-chemotherapy 60 d.The differences of the mean ADC values in differ-ent time points were statistically significant (P < 0.05).Conclusion DWI and ADC value can dynamically,quantitatively and early detect and monitor the chemotherapy response of advanced gastric carcinoma.

The global outbreak of the coronavirus disease 2019 (COVID-19) led to the suspension of most treatments with assisted reproductive technique (ART). However, with the recent successful control of the pandemic in China, there is an urgent public need to resume full reproductive care. To determine whether the COVID-19 pandemic had any adverse effects on female fertility and the pregnancy outcomes of women undergoing ART, a systematic review and meta-analysis was conducted using the electronic Chinese and English databases. Dichotomous outcomes were summarized as prevalence, and odds ratios (ORs) and continuous outcomes as standardized mean difference (SMD) with 95% confidence interval (CI). The risk of bias and subgroup analyses were assessed using Stata/SE 15.1 and R 4.1.2. The results showed that compared with women treated by ART in the pre-COVID-19 time frame, women undergoing ART after the COVID-19 pandemic exhibited no significant difference in the clinical pregnancy rate (OR 1.07, 95% CI 0.97 to 1.19; I²=0.0%), miscarriage rate (OR 0.95, 95% CI 0.79 to 1.14; I²=38.4%), embryo cryopreservation rate (OR 2.90, 95% CI 0.17 to 48.13; I²=85.4%), and oocyte cryopreservation rate (OR 0.30, 95% CI 0.03 to 3.65; I²=81.6%). This review provided additional evidence for gynecologists to guide the management of women undergoing ART treatment during the COVID-19 pandemic timeframe.
COVID-19 ; Female ; Humans ; Pandemics ; Pregnancy ; Pregnancy Outcome/epidemiology* ; Pregnancy Rate ; Reproductive Techniques, Assisted